Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2168 January 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
	Address:	
Fax Number:		Fax Number:
Initial application — chronic lymphocytic leukaemia (CLL) Applications from any relevant practitioner. Approvals valid for 6 months. Prerequisites(tick boxes where appropriate) Patient has chronic lymphocytic leukaemia (CLL) requiring therapy and Patient has not previously received funded ibrutinib		
and Ibrutinib is to be used as monotherapy and		
There is documentation confirming that patient has 17p deletion or TP53 mutation and Patient has experienced intolerable side effects with venetoclax monotherapy or		
Patient has received at least one prior immunochemotherapy for CLL and Patient's CLL has relapsed within 36 months of previous treatment and Patient has experienced intolerable side effects with venetoclax in combination with rituximab regimen or		
Patient's CLL is refractory to or has relapsed within 36 months of a venetoclax regimen		
Renewal — chronic lymphocytic leukaemia (CLL) Current approval Number (if known):		
No evidence of clinical disease progression and The treatment remains appropriate and the patient is benefitting from treatment		

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma (SLL) and B-cell prolymphocytic leukaemia (B-PLL)*. Indications marked with * are Unapproved indications.

I confirm the above details are correct and that in signing this form I understand I may be audited.